EDISON values SYGNIS at 37.5 million euros €
- This valuation amply exceeds the current market quotation and ascribes the shares a potential growth rate of more than 50%.
- EDISON base their analysis on three of SYGNIS’ current products, including QualiPhi, which was licensed to Qiagen and will be launched in the third quarter of this year.
Madrid/Heidelberg, 10 July 2013– EDISON, international analysts who specialize in listed companies of the industry, recently published a thorough analysis of the biotech company SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard segment of the German Stock Exchange).
As a result of EDISON’s analysis of the company, the objective value of SYGNIS, taking into account the launch of QualiPhi in the third quarter of 2013 – licensed by Qiagen – as well as the license of two further products this year: PrimPol and Double Switch, would reach 37.5 million euros.
SYGNIS shares were listed at 2.63 euros last Tuesday at Frankfurt’s stock market, with capitalization close to 25 million euros. Therefore, EDISON’s estimations place the value of the shares at a potential increase of more than 50% for its shareholders this year.
In order to undertake the analysis of the share value of SYGNIS, EDISON focused on the predicted income of three products: QualiPhi, PrimPol and Double Switch. Meanwhile, EDISON have not considered any additional products the company has been developing (DNA repair kit), thus the income assumptions can be considered conservative.
QUALIPHI®, is an improved version of DNA Polymerase Phi 29. It was generated in Professor Margarita Salas’ lab, with the collaboration of Professor Luis Blanco, in the CSIC. Using this as a starting point, the X-POL team (GENETRIX Group), known today as SYGNIS, developed a product of unique characteristics, focused on isothermal DNA amplification, which was licensed to Qiagen in July 2012. The commercialization of this product will start in the third quarter of 2013.
PrimPol is a new enzyme with the characteristics of a primase (it does not need random primers to initiate the process) and a polymerase with elevated proofreading capacity and high processivity, making it an optimal tool not only for DNA amplification, but also for simplifying some technical aspects of RNA amplification.
DoubleSwitch is a cellular technology that identifies and quantifies interactions between proteins in a cell. Knowledge about the mechanism in which proteins interact is particularly relevant not only in proteomics, a field of growing interest, but also to develop personalized drugs.
Press Release as PDF